COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravisArticle Published on 2023-04-012023-07-10 Journal: Acta neurologica Belgica [Category] COVID19(2023년), [키워드] COVID-19 infection myasthenia gravis SARS-CoV-2 vaccination. [DOI] 10.1007/s13760-022-02121-w PMC 바로가기
Brief psychotic disorder revealing a SARS-COV-2 encephalopathy in a patient with myasthenia gravis: A case reportCase Reports Published on 2023-04-012023-07-10 Journal: L'Encéphale [Category] COVID19(2023년), [키워드] myasthenia gravis Myasthénie auto-immune Psychose psychotic disorder SARS-CoV-2. [DOI] 10.1016/j.encep.2022.04.001 PMC 바로가기 [Article Type] Case Reports
BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron wavesArticle Published on 2022-12-012022-11-16 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 변종, [키워드] Administered Affect Alpha BNT162b2 mRNA BNT162b2 mRNA vaccine contribute COVID-19 COVID-19 mortality COVID-19 vaccine develop disease General population Mild morbidity and mortality Myasthenia myasthenia gravis outcome Patient patients raise reduced risk Respiratory failure risk risk of COVID-19 Safety SARS-CoV-2 SARS-CoV-2 variants severe COVID-19 severe disease significantly higher vaccination Vaccine vaccine dose vaccine. [DOI] 10.1007/s00415-022-11303-8 PMC 바로가기
COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2Review Published on 2022-12-012023-07-10 Journal: Brain and Behavior [Category] COVID19(2023년), [키워드] Guillain-barrè syndrome immunoglobulins Infection myasthenia gravis pyridostigmine bromide Severe acute respiratory syndrome coronavirus 2. [DOI] 10.1002/brb3.2789 PMC 바로가기 [Article Type] Review
New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case seriesCase Reports Published on 2022-10-012023-07-10 Journal: Neurological Sciences [Category] COVID19(2023년), [키워드] COVID-19 mRNA. myasthenia gravis SARS-CoV-2 Vaccine [DOI] 10.1007/s10072-022-06284-5 PMC 바로가기 [Article Type] Case Reports
SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literatureReview Published on 2022-10-012023-07-10 Journal: Neuromuscular disorders : NMD [Category] COVID19(2023년), [키워드] myasthenia gravis SARS-CoV-2 vaccination. [DOI] 10.1016/j.nmd.2022.09.001 PMC 바로가기 [Article Type] Review
A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment에쿨리주맙 치료를 받고 있는 전신 중증 근무력증 환자의 경미한 COVID-19 감염 경과Article Published on 2022-09-012022-09-12 Journal: Neurological Sciences [Category] MERS, 진단, [키워드] Course COVID-19 infection Mild myasthenia gravis Patient Treatment [DOI] 10.1007/s10072-022-06108-6 PMC 바로가기 [Article Type] Article
Nervous system manifestations related to COVID-19 and their possible mechanismsReview article Published on 2022-09-012022-10-05 Journal: Brain research bulletin [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] ACE2angiotensin-converting enzyme 2 Acute inflammatory demyelinating polyneuropathy Acute motor axonal neuropathy acute motor sensory axonal neuropathy Acute necrotizing encephalopathy acute respiratory syndrome ADAlzheimer's disease ADRDAlzheimer's disease and related dementia AIDPacute inflammatory demyelinating polyneuropathy Alzheimer's disease Alzheimer's disease and related dementia AMANacute motor axonal neuropathy AMSANacute motor sensory axonal neuropathy ANEacute necrotizing encephalopathy Angiotensin Type 1 receptor angiotensin-converting enzyme 2 AT1 receptorAngiotensin Type 1 receptor BBBBlood-brain barrier blood-brain barrier BLSbrain lymphatic systems brain lymphatic systems CDCCenters for Disease Control and Prevention Centers for Disease Control and Prevention Central nervous system cerebral venous system Cerebral venous thrombosis cerebrospinal fluid CKcreatine kinase clinician CNS CNSCentral Nervous System complex coronavirus COVID-19 COVID-19novel coronavirus disease creatine kinase CSCytokine storm CSFcerebrospinal fluid CVScerebral venous system CVTCerebral Venous Thrombosis Cytokine storm damage-related molecular patterns DAMPdamage-related molecular patterns disease disease modification therapy Diseases DMTdisease modification therapy Effect Electromyography/nerve conduction EMG/NCSElectromyography/nerve conduction GBSGuillain-Barré syndrome Guillain-barrè syndrome ICHIntracranial hemorrhage indirect effects Infection intracranial hemorrhage Invasion knowledge LMWHlow molecular weight heparin low molecular weight heparin manifestation mechanism MFSmiller fisher syndrome MGmyasthenia gravis Miller fisher syndrome MSMultiple sclerosis multiple sclerosis myasthenia gravis nAChnicotine-type acetylcholine nervous nervous system Neuromyelitis optica spectrum disorders Neuropsychiatric nicotine-type acetylcholine NMOSDneuromyelitis optica spectrum disorders novel coronavirus disease OBOlfactory bulb olfactory bulb pathway Pattern recognition receptors Peripheral nervous system PNSPeripheral nervous system Post-traumatic stress disorder PRRpattern recognition receptors PTSDpost-traumatic stress disorder RASRenin-angiotensin system renin-angiotensin system researcher S Proteinspike protein SARS-CoV-2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome coronavirus 2 SNSubstantia nigra Spike protein substantia nigra UFHunfractionated heparin unfractionated heparin Vascular endothelium VEVascular endothelium [DOI] 10.1016/j.brainresbull.2022.06.014 [Article Type] Review article
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience중증 근무력증 환자에서 SARS-Cov-2 백신 접종의 안전성 및 내약성: 다기관 경험Multicenter Study Published on 2022-08-012022-09-12 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, [키워드] Administered Clinical characteristics collected Complication contributed COVID-19 pandemic Diagnosis dose eight enrolled Fever Frequency high risk higher risk information lack large cohort local pain mRNA COVID-19 vaccines multicenter myasthenia gravis offered Patient patients reported Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine serological severe COVID-19 Side effect significantly higher Spontaneous subgroups subject Support Symptom Tolerability tyrosine vaccination vaccination. Vaccine vaccine dose Vaccine hesitancy were assessed worsened worsening [DOI] 10.1111/ene.15348 PMC 바로가기 [Article Type] Multicenter Study
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumabCOVID-19에 감염된 전신성 중증 근무력증 환자는 에쿨리주맙을 계속해야 합니다Article Published on 2022-07-012022-09-12 Journal: Neurological Sciences [Category] MERS, 진단, [키워드] complement coronavirus disease COVID-19 eculizumab Generalized humanized monoclonal antibody indicated infected with COVID-19 Infection inhibitor myasthenia gravis myasthenia gravis. outcome Patient [DOI] 10.1007/s10072-022-05922-2 PMC 바로가기 [Article Type] Article